U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Malignant pleural mesothelioma

MedGen UID:
208810
•Concept ID:
C0812413
•
Neoplastic Process
Synonym: Malignant mesothelioma of pleura
SNOMED CT: Malignant pleural mesothelioma (254645002); Malignant mesothelioma of pleura (254645002)
 
HPO: HP:0100002
Monarch Initiative: MONDO:0005112

Definition

A malignant mesothelioma originating from cells of the pleura (the thin layer of mesothelium lining the lungs). Pleural mesothelioma is the most common form of mesothelioma. [from HPO]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVMalignant pleural mesothelioma

Professional guidelines

PubMed

Perspectives on the Treatment of Malignant Pleural Mesothelioma.
Janes SM, Alrifai D, Fennell DA
N Engl J Med 2021 Sep 23;385(13):1207-1218. doi: 10.1056/NEJMra1912719. PMID: 34551230
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM
Eur Respir J 2020 Jun;55(6) Epub 2020 Jun 11 doi: 10.1183/13993003.00953-2019. PMID: 32451346
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I
Eur Respir Rev 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. PMID: 27903668Free PMC Article

Curated

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Mesothelioma: Pleural, 2022

Recent clinical studies

Etiology

Update on Diagnosing and Reporting Malignant Pleural Mesothelioma.
Savic I, Myers J
Acta Med Acad 2021 Apr;50(1):197-208. doi: 10.5644/ama2006-124.335. PMID: 34075773
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA
Curr Opin Oncol 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. PMID: 33186182
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A, Mazieres J, Greillier L, Lantuejoul S, Dô P, Bylicki O, Monnet I, Corre R, Audigier-Valette C, Locatelli-Sanchez M, Molinier O, Guisier F, Urban T, Ligeza-Poisson C, Planchard D, Amour E, Morin F, Moro-Sibilot D, Zalcman G; French Cooperative Thoracic Intergroup
Lancet Oncol 2019 Feb;20(2):239-253. Epub 2019 Jan 16 doi: 10.1016/S1470-2045(18)30765-4. PMID: 30660609
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230
Malignant pleural mesothelioma.
Hughes RS
Am J Med Sci 2005 Jan;329(1):29-44. doi: 10.1097/00000441-200501000-00007. PMID: 15654178

Diagnosis

Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA
Curr Opin Oncol 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. PMID: 33186182
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME
Clin Respir J 2018 Mar;12(3):839-847. Epub 2017 Jan 11 doi: 10.1111/crj.12597. PMID: 27997741
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I
Eur Respir Rev 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. PMID: 27903668Free PMC Article
Malignant pleural mesothelioma.
Chen SE, Pace MB
Am J Health Syst Pharm 2012 Mar 1;69(5):377-85. doi: 10.2146/ajhp110281. PMID: 22345416
Malignant pleural mesothelioma.
Raja S, Murthy SC, Mason DP
Curr Oncol Rep 2011 Aug;13(4):259-64. doi: 10.1007/s11912-011-0177-9. PMID: 21573909

Therapy

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G
Ann Oncol 2022 May;33(5):488-499. Epub 2022 Feb 3 doi: 10.1016/j.annonc.2022.01.074. PMID: 35124183
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodríguez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman G
Lancet 2021 Jan 30;397(10272):375-386. Epub 2021 Jan 21 doi: 10.1016/S0140-6736(20)32714-8. PMID: 33485464
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA
Curr Opin Oncol 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. PMID: 33186182
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P
J Clin Oncol 2003 Jul 15;21(14):2636-44. doi: 10.1200/JCO.2003.11.136. PMID: 12860938

Prognosis

Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆).
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, Opitz I, Scherpereel A, Reck M; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Ann Oncol 2022 Feb;33(2):129-142. Epub 2021 Nov 30 doi: 10.1016/j.annonc.2021.11.005. PMID: 34861373
Clinical Features and Treatment Outcome of Malignant Pleural Mesothelioma.
Mencoboni M, Filiberti RA, Taveggia P, Grosso F, Pasello G, Del Corso L, Muzio A, Polo V, Zucali P, Ceresoli GL, Soto Parra HJ, Auriati L, Simonassi C
Oncol Res Treat 2017;40(6):364-369. Epub 2017 May 9 doi: 10.1159/000464410. PMID: 28472807
Malignant pleural mesothelioma.
Chen SE, Pace MB
Am J Health Syst Pharm 2012 Mar 1;69(5):377-85. doi: 10.2146/ajhp110281. PMID: 22345416
Malignant pleural mesothelioma.
Ho L, Sugarbaker DJ, Skarin AT
Cancer Treat Res 2001;105:327-73. doi: 10.1007/978-1-4615-1589-0_13. PMID: 11224994
Pericardial mesothelioma.
Vigneswaran WT, Stefanacci PR
Curr Treat Options Oncol 2000 Oct;1(4):299-302. doi: 10.1007/s11864-000-0045-6. PMID: 12057155

Clinical prediction guides

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G
Ann Oncol 2022 May;33(5):488-499. Epub 2022 Feb 3 doi: 10.1016/j.annonc.2022.01.074. PMID: 35124183
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA
Curr Opin Oncol 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. PMID: 33186182
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME
Clin Respir J 2018 Mar;12(3):839-847. Epub 2017 Jan 11 doi: 10.1111/crj.12597. PMID: 27997741
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I
Eur Respir Rev 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. PMID: 27903668Free PMC Article
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, Molinier O, Corre R, Monnet I, Gounant V, Rivière F, Janicot H, Gervais R, Locher C, Milleron B, Tran Q, Lebitasy MP, Morin F, Creveuil C, Parienti JJ, Scherpereel A; French Cooperative Thoracic Intergroup (IFCT)
Lancet 2016 Apr 2;387(10026):1405-1414. Epub 2015 Dec 21 doi: 10.1016/S0140-6736(15)01238-6. PMID: 26719230

Recent systematic reviews

Cytoreductive surgery with hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma: a systematic review.
Dawson AG, Kutywayo K, Mohammed SB, Fennell DA, Nakas A
Thorax 2023 Apr;78(4):409-417. Epub 2022 Apr 11 doi: 10.1136/thoraxjnl-2021-218214. PMID: 35410957
Pathology of Malignant Pleural Mesothelioma.
Hung YP, Chirieac LR
Thorac Surg Clin 2020 Nov;30(4):367-382. doi: 10.1016/j.thorsurg.2020.08.007. PMID: 33012427
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
Scherpereel A, Opitz I, Berghmans T, Psallidas I, Glatzer M, Rigau D, Astoul P, Bölükbas S, Boyd J, Coolen J, De Bondt C, De Ruysscher D, Durieux V, Faivre-Finn C, Fennell D, Galateau-Salle F, Greillier L, Hoda MA, Klepetko W, Lacourt A, McElnay P, Maskell NA, Mutti L, Pairon JC, Van Schil P, van Meerbeeck JP, Waller D, Weder W, Cardillo G, Putora PM
Eur Respir J 2020 Jun;55(6) Epub 2020 Jun 11 doi: 10.1183/13993003.00953-2019. PMID: 32451346
Radical multimodality therapy for malignant pleural mesothelioma.
Abdel-Rahman O, Elsayed Z, Mohamed H, Eltobgy M
Cochrane Database Syst Rev 2018 Jan 8;1(1):CD012605. doi: 10.1002/14651858.CD012605.pub2. PMID: 29309720Free PMC Article
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review.
Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA
Br J Cancer 2017 Mar 14;116(6):731-741. Epub 2017 Feb 7 doi: 10.1038/bjc.2017.22. PMID: 28170372Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • NCCN, 2022
      NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Mesothelioma: Pleural, 2022

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...